General
Preferred name
KANAMYCIN
Synonyms
Bekanamycin ()
Kanamycin A monosulfate ()
Kanamycin monosulfate ()
Ophtalmokalixan ()
KANAMYCIN SULFATE ()
KANAMYCIN A SULFATE ()
Kanamycin (sulfate) ()
Kanamycin A (sulfate) ()
Kanamycin monosulfate, Ophtalmokalixan ()
Kanamycini monosulfas ()
Kanamycin a sulfate monohydrate ()
Kanamycin monosulphate ()
Kanamycin a sulphate ()
Klebcil ()
Kanamycin sulfate monohydrate ()
Kantrex ()
NSC-757068 ()
Kanamycin a sulfate ()
Kanamycins ()
P&D ID
PD009763
CAS
25389-94-0
11025-65-3
8063-07-8
59-01-8
Tags
natural product
drug
available
Approved by
FDA
First approval
1973
Drug Status
investigational
approved
vet_approved
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
Mild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Amikacin accumulates in proximal renal tubular cells. Tubular cell regeneration occurs despite continued drug exposure. Toxicity usually occurs several days following initiation of therapy. May cause irreversible ototoxicity. Otoxocity appears to be correlated to cumulative lifetime exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing is lost first with progression leading to loss of low frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness and loss of balance.; Oral LD50 is 17500 mg/kg in mice, over 4 g/kg in rats, and over 3 g/kg in rabbits.
DESCRIPTION
Kanamycin (also known as kanamycin A) is the main fermentation product of Streptomyces kanamyceticus . Additional products have been subsequently identified, including (kanamycin B), kanamycin C (PubChem CID: 439582), kanamycin D (PubChem CID: 10368104) and kanamycin X (PubChem CID: 25202222).
Kanamycin has activity against Gram-positive and Gram-negative bacteria and belongs to the aminoglycoside class of antibacterial compounds. (GtoPdb)
Kanamycin has activity against Gram-positive and Gram-negative bacteria and belongs to the aminoglycoside class of antibacterial compounds. (GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
7
Compound Sets
16
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
61
Molecular Weight
484.24
Hydrogen Bond Acceptors
15
Hydrogen Bond Donors
11
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
0
cLogP
-7.29
TPSA
282.61
Fraction CSP3
1.0
Chiral centers
15.0
Largest ring
6.0
QED
0.17
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
16S ribosome
30S ribosome
antibiotic
Bacterial
Antibiotics,Antibiotics for Mammalian Cell Culture,Antibiotics for Plant Cell Culture,Selection Antibiotics for Transfected Cell
MOA
ribosome inhibitor
bacterial 30S ribosomal subunit inhibitor
Indication
gram-negative bacterial infections
Therapeutic Class
Antibiotics
Source data
